Case report: A case of advanced gastric cancer with multiple skin metastases, with significant relief from immunotherapy
We reported a rare case of female gastric cancer. The patient had undergone subtotal gastrectomy and chemotherapy 13 years ago, followed by a subsequent surgery of residual stomach, partial jejunum, and partial colon resection 11 years later. The pathological examination revealed poorly differentiated stomach adenocarcinoma, Lauren classification: diffuse type. The patient received 2 cycles of SOX chemotherapy. Two years later, cauliflower-like skin nodules, which were surgically excised, appeared on the back. The histopathological examination showed a spindle cell tumor; no specific anti-tumor treatment was administered. ...
Source: Frontiers in Immunology - February 29, 2024 Category: Allergy & Immunology Source Type: research
Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent
CONCLUSION: MRI/FMI with a low dose of ZD2-Gd-DOTA-Cy7 enables sensitive imaging of PDAC and the quantitative assessment of fibrotic changes during AG chemotherapy, which shows potential clinical applications for precise diagnosis, post-treatment monitoring, and disease management.PMID:38372766 | DOI:10.1007/s00259-024-06617-w (Source: Molecular Medicine)
Source: Molecular Medicine - February 19, 2024 Category: Molecular Biology Authors: Wenjia Zhang Xiaolong Liang Xinyu Zhang Wei Tong Guangyuan Shi Haozhuo Guo Zhengyu Jin Jie Tian Yang Du Huadan Xue Source Type: research
Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent
CONCLUSION: MRI/FMI with a low dose of ZD2-Gd-DOTA-Cy7 enables sensitive imaging of PDAC and the quantitative assessment of fibrotic changes during AG chemotherapy, which shows potential clinical applications for precise diagnosis, post-treatment monitoring, and disease management.PMID:38372766 | DOI:10.1007/s00259-024-06617-w (Source: Cancer Control)
Source: Cancer Control - February 19, 2024 Category: Cancer & Oncology Authors: Wenjia Zhang Xiaolong Liang Xinyu Zhang Wei Tong Guangyuan Shi Haozhuo Guo Zhengyu Jin Jie Tian Yang Du Huadan Xue Source Type: research
Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent
ConclusionMRI/FMI with a low dose of ZD2-Gd-DOTA-Cy7 enables sensitive imaging of PDAC and the quantitative assessment of fibrotic changes during AG chemotherapy, which shows potential clinical applications for precise diagnosis, post-treatment monitoring, and disease management. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - February 19, 2024 Category: Nuclear Medicine Source Type: research
Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
CONCLUSION: Albumin-bound paclitaxel demonstrates good safety and tolerability in HIPEC during and after GC surgery, without increasing the risk of intraoperative complications.PMID:38367177 | DOI:10.1007/s12029-024-01031-9 (Source: Cancer Control)
Source: Cancer Control - February 17, 2024 Category: Cancer & Oncology Authors: Jingxiang Zhou Xiaopeng Cai Zhao Lu Bin Xiong Chunwei Peng Source Type: research
Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
ConclusionAlbumin-bound paclitaxel demonstrates good safety and tolerability in HIPEC during and after GC surgery, without increasing the risk of intraoperative complications. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - February 17, 2024 Category: Cancer & Oncology Source Type: research
Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma
ConclusionThe Camrelizumab-TP regimen demonstrated promising results for advanced hypopharyngeal/laryngeal SCC patients, exhibiting high response rates, OS, and LFS, positioning it as a potential primary option for laryngeal preservation. Further comprehensive, randomized controlled studies are imperative to validate these initial observations and elucidate the regimen's full clinical efficacy in optimizing laryngeal outcomes. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - February 15, 2024 Category: Cancer & Oncology Source Type: research
Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives
Conclusion: Nab-paclitaxel plus camrelizumab exhibited modest activity and mild toxicity in treating epithelioid sarcoma, angiosarcoma, and fibrosarcoma. The overall effectiveness of this treatment regimen for advanced STS is relatively low. Further research on combining nab-paclitaxel with effective drugs, including chemotherapy and targeted agents, for these specific STS subtypes is needed. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - February 1, 2024 Category: Drugs & Pharmacology Source Type: research
Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy
In this report, we present a case featuring a rare epidermal growth factor receptor (EGFR) mutation accompanied by high programmed death-ligand 1 (PD-L1) expression, demonstrating remarkable therapeutic efficacy through a combination of immunotherapy and chemotherapy. A 77-year-old male with no family history of cancer suffered from upper abdominal pain for more than half months in August 2020 and was diagnosed with stage IV (cT3N3M1c) lung squamous cell carcinoma (LUSC) harboring both a rare EGFR p.G719C mutation and high expression of PD-L1 (tumor proportion score [TPS] = 90%). Treatment with the second-generation target...
Source: Frontiers in Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research
Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies
CONCLUSION: Nab-PTX monotherapy may be an effective subsequent treatment option after ICI treatment.PMID:38290482 | DOI:10.1159/000535994 (Source: Oncology)
Source: Oncology - January 30, 2024 Category: Cancer & Oncology Authors: Koki Nakashima Yukihiro Umeda Yoshiki Demura Tomoaki Sonoda Toshihiko Tada Makiko Yamaguchi Masaki Anzai Maiko Kadowaki Masahiro Oi Chisato Honjo Miho Mitsui Yuko Waseda Tamotsu Ishizuka Source Type: research
Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report
ConclusionsThe present case suggests that multidisciplinary treatment consisting of a combination of recent chemotherapy and CIRT may be beneficial for unresectable LA PDAC. However, further studies are required to assess the true efficacy of this treatment strategy. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - January 11, 2024 Category: General Medicine Source Type: research
Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - January 10, 2024 Category: Allergy & Immunology Authors: Fang Yan Longpei Chen Mingzhen Ying Jie Li Qiang Fu Source Type: research
Modulating the tumoral SPARC content to enhance albumin-based drug delivery for cancer therapy
J Control Release. 2024 Jan 4:S0168-3659(24)00001-4. doi: 10.1016/j.jconrel.2023.12.057. Online ahead of print.ABSTRACTInsufficient delivery of therapeutic agents into solid tumors by systemic administration remains a major challenge in cancer treatment. Secreted protein acidic and rich in cysteine (SPARC) has high binding affinity to albumin and has been shown to enhance the penetration and uptake of albumin-based drug carriers in tumors. Here, we developed a strategy to alter the tumor microenvironment (TME) by upregulating SPARC to enhance the delivery efficiency of albumin-based drug carriers into tumors. We prepared a...
Source: Cancer Control - January 6, 2024 Category: Cancer & Oncology Authors: Binbin Zheng Yanping Chen Liman Niu Xinyuan Zhang Yubin Yang Shanzhao Wang Wei Chen Zhiming Cai Wei Huang Weiren Huang Source Type: research
